Search company, investor...
Intralytix company logo

Intralytix

intralytix.com

Stage

Grant - II | Alive

Total Raised

$17.75M

About Intralytix

Intralytix is a biotechnology company focused on the discovery, production, and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Headquarters Location

8681 Robert Fulton Drive

Columbia, Maryland, 21046,

United States

+1 410 913 7943

Missing: Intralytix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intralytix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Intralytix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intralytix is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Intralytix Patents

Intralytix has filed 1 patent.

The 3 most popular patent topics include:

  • Bacteriology
  • Digestive system
  • Lactobacillaceae
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2016

7/14/2020

Bacteriophages, Molecular biology, Virology, Virus families, Bacteriology

Grant

Application Date

1/21/2016

Grant Date

7/14/2020

Title

Related Topics

Bacteriophages, Molecular biology, Virology, Virus families, Bacteriology

Status

Grant

Latest Intralytix News

Intralytix receives Phase II Fast Track NIH SBIR contract

Aug 24, 2022

Intralytix receives Phase II Fast Track NIH SBIR contract to continue development of a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications. Columbia, Maryland, USA. – August 22, 2022 – Intralytix, Inc. announced today that it has received a Phase II contract in the amount of $1,498,045. This contract is made through the Small Business Innovation Research (SBIR)  program from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This project is the continuation of a successfully completed NIAID-funded Phase I contract (see Intralytix, Inc.) and will further leverage Intralytix’s existing proprietary PhageSelector™ program, big data, and manufacturing know-how along with machine learning to advance an artificial intelligence (AI)-based universal manufacturing platform, the PhageEngine™, to deliver methods for producing high titer, high quality bacteriophage preparations suitable for clinical applications. Dr. Alexander Sulakvelidze, President and CEO of Intralytix and the Principal Investigator of the SBIR contract, commented, "We are very pleased to further extend this work with support from NIH after successfully competing Phase I of the project. The resulting technology will significantly increase Intralytix’s capabilities as well as help advance the phage biocontrol and phage therapy fields in general and will ultimately have a very significant positive impact on public health. We look forward to continuing this important project in collaboration with NIH. "

Intralytix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intralytix Rank

Intralytix Frequently Asked Questions (FAQ)

  • Where is Intralytix's headquarters?

    Intralytix's headquarters is located at 8681 Robert Fulton Drive, Columbia.

  • What is Intralytix's latest funding round?

    Intralytix's latest funding round is Grant - II.

  • How much did Intralytix raise?

    Intralytix raised a total of $17.75M.

  • Who are the investors of Intralytix?

    Investors of Intralytix include National Institute of Food and Agriculture, National Institute of Allergy and Infectious Diseases, Paycheck Protection Program and Lesaffre.

  • Who are Intralytix's competitors?

    Competitors of Intralytix include Biolog, GangaGen, Bloomage BioTech, Pronucleotein, Agrisoma BioSciences and 12 more.

Compare Intralytix to Competitors

C
Chef Solutions

Chef Solutions is a corporate entity consisting of the Orval Kent Foods Co. Orval Kent is a provider of prepared foods and meal solutions to the retail and food service industries.

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

Unima Logo
Unima

Unima developed a diagnostic and disease surveillance technology for infectious diseases which allows doctors, nurses and community health workers to diagnose diseases directly on the point of care without the use of any lab equipment.

A
Aimsbio

AimsBio is a high throughput analytics service provider and biotechnology company developing assays to aid the plant breeding, seed production, ethanol production, feed, food production, health, and pharmaceutical markets.

Bharat Biotech Logo
Bharat Biotech

Bharat Biotech is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech is engaged in developing vaccines and bio-therapeutics through and collaborative research.

K
Ktedogen s.r.l.

Ktedogen is a research-based biotechnology company focussed on the discovery and development of new products from microbial sources. Its technology is based on the isolation from the environment of groups of micro-organisms with the ability to synthesize a variety of natural products. These strains are evaluated in targeted screening programs for the production of classes of antibiotics, of new biological catalysts and for improved processes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.